633 related articles for article (PubMed ID: 34736911)
1. Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population.
Corey L; Cote ML; Ruterbusch JJ; Vezina A; Winer I
Am J Obstet Gynecol; 2022 Apr; 226(4):541.e1-541.e13. PubMed ID: 34736911
[TBL] [Abstract][Full Text] [Related]
2. Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis.
Bregar AJ; Alejandro Rauh-Hain J; Spencer R; Clemmer JT; Schorge JO; Rice LW; Del Carmen MG
Gynecol Oncol; 2017 Apr; 145(1):114-121. PubMed ID: 28159409
[TBL] [Abstract][Full Text] [Related]
3. Black and Hispanic women are less likely than white women to receive guideline-concordant endometrial cancer treatment.
Kaspers M; Llamocca E; Quick A; Dholakia J; Salani R; Felix AS
Am J Obstet Gynecol; 2020 Sep; 223(3):398.e1-398.e18. PubMed ID: 32142825
[TBL] [Abstract][Full Text] [Related]
4. Incidence and effects on mortality of venous thromboembolism in elderly women with endometrial cancer.
Rauh-Hain JA; Hariton E; Clemmer J; Clark RM; Hall T; Boruta DM; Schorge JO; Del Carmen MG
Obstet Gynecol; 2015 Jun; 125(6):1362-1370. PubMed ID: 26000507
[TBL] [Abstract][Full Text] [Related]
5. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS; Brasky TM; Cohn DE; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel C; Boggess JF; Pearl ML; Ioffe OB; Deng W; Miller DS; Brinton LA
Int J Cancer; 2018 Mar; 142(6):1102-1115. PubMed ID: 29063589
[TBL] [Abstract][Full Text] [Related]
6. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS; Cohn DE; Brasky TM; Zaino R; Park K; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel CI; Boggess JF; Pearl ML; Ioffe OB; Randall ME; Brinton LA
Am J Obstet Gynecol; 2018 Nov; 219(5):459.e1-459.e11. PubMed ID: 30096321
[TBL] [Abstract][Full Text] [Related]
7. Racial disparities in treatment of high-grade endometrial cancer in the Medicare population.
Rauh-Hain JA; Buskwofie A; Clemmer J; Boruta DM; Schorge JO; Del Carmen MG
Obstet Gynecol; 2015 Apr; 125(4):843-851. PubMed ID: 25751197
[TBL] [Abstract][Full Text] [Related]
8. More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer.
Barrington DA; Sinnott JA; Nixon D; Padamsee TJ; Cohn DE; Doll KM; Donneyong MM; Felix AS
Am J Obstet Gynecol; 2022 Aug; 227(2):244.e1-244.e17. PubMed ID: 35283091
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
10. The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women.
Cote ML; Ruterbusch JJ; Olson SH; Lu K; Ali-Fehmi R
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1407-15. PubMed ID: 26290568
[TBL] [Abstract][Full Text] [Related]
11. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
[TBL] [Abstract][Full Text] [Related]
12. Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER study.
Saris DH; Smith AJB; Brensinger C; Kim SH; Haggerty AF; Latif N; Cory L; Giuntoli RL; Morgan MA; Lin LL; Ko EM
Gynecol Oncol Rep; 2022 Apr; 40():100922. PubMed ID: 35242979
[TBL] [Abstract][Full Text] [Related]
13. The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.
Lee JK; Ghanem AI; Modh A; Burmeister C; Mahmoud O; Maxwell GL; Elshaikh MA
Brachytherapy; 2018; 17(2):319-325. PubMed ID: 29174935
[TBL] [Abstract][Full Text] [Related]
14. Racial disparities in young women with endometrial cancer.
Mukerji B; Baptiste C; Chen L; Tergas AI; Hou JY; Ananth CV; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2018 Mar; 148(3):527-534. PubMed ID: 29307452
[TBL] [Abstract][Full Text] [Related]
15. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
16. Impact of quality of care on racial disparities in survival for endometrial cancer.
Huang AB; Huang Y; Hur C; Tergas AI; Khoury-Collado F; Melamed A; St Clair CM; Hou JY; Ananth CV; Neugut AI; Hershman DL; Wright JD
Am J Obstet Gynecol; 2020 Sep; 223(3):396.e1-396.e13. PubMed ID: 32109459
[TBL] [Abstract][Full Text] [Related]
17. Racial disparities in outcomes for high-grade uterine cancer: A California cancer registry study.
Baskovic M; Lichtensztajn DY; Nguyen T; Karam A; English DP
Cancer Med; 2018 Sep; 7(9):4485-4495. PubMed ID: 30123978
[TBL] [Abstract][Full Text] [Related]
18. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma.
Xiang M; Kidd EA
J Gynecol Oncol; 2020 Jul; 31(4):e39. PubMed ID: 31912686
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
